Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Drug safety and efficacy evaluation of sertindole for schizophrenia.

Karamatskos E, Lambert M, Mulert C, Naber D.

Expert Opin Drug Saf. 2012 Nov;11(6):1047-62. doi: 10.1517/14740338.2012.726984. Review.

PMID:
22992213
2.

Sertindole in schizophrenia: efficacy and safety issues.

Muscatello MR, Bruno A, Micali Bellinghieri P, Pandolfo G, Zoccali RA.

Expert Opin Pharmacother. 2014 Sep;15(13):1943-53. doi: 10.1517/14656566.2014.947960. Review.

PMID:
25084209
3.

Sertindole for schizophrenia.

Lewis R, Bagnall AM, Leitner M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715. Review.

PMID:
16034864
4.

Emerging treatments in the management of schizophrenia - focus on sertindole.

Muscatello MR, Bruno A, Pandolfo G, Micò U, Settineri S, Zoccali R.

Drug Des Devel Ther. 2010 Sep 7;4:187-201. doi: 10.2147/DDDT.S6591. Review.

5.

Sertindole for the treatment of schizophrenia.

Azorin JM, Kaladjian A, Fakra E, Adida M.

Expert Opin Pharmacother. 2010 Dec;11(18):3053-64. doi: 10.1517/14656566.2010.536217. Review.

PMID:
21080854
6.

A review of the efficacy, tolerability and safety of sertindole in clinical trials.

Perquin L, Steinert T.

CNS Drugs. 2004;18 Suppl 2:19-30; discussion 41-3. Review.

PMID:
15461313
7.

Efficacy and safety of sertindole in schizophrenia: a clinical review.

Zoccali RA, Bruno A, Muscatello MR.

J Clin Psychopharmacol. 2015 Jun;35(3):286-95. doi: 10.1097/JCP.0000000000000305. Review.

PMID:
25830594
8.

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.

Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB.

Int Clin Psychopharmacol. 1997 Feb;12 Suppl 1:S29-35. Review.

PMID:
9179641
9.

Sertindole: efficacy and safety in schizophrenia.

Lindström E, Levander S.

Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. Review.

PMID:
16925508
10.

A review of the safety and tolerability of sertindole.

Hale AS.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S65-70. Review.

PMID:
9690973
11.

Sertindole: dilemmas for its use in clinical practice.

Pae CU.

Expert Opin Drug Saf. 2013 May;12(3):321-6. doi: 10.1517/14740338.2013.773971.

PMID:
23432404
12.

Sertindole for schizophrenia.

Lewis R, Bagnall A, Leitner M.

Cochrane Database Syst Rev. 2000;(2):CD001715. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD001715.

PMID:
10796657
13.

Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.

Pezawas L, Quiner S, Moertl D, Tauscher J, Barnas C, Küfferle B, Wolf R, Kasper S.

Int Clin Psychopharmacol. 2000 Jul;15(4):207-14.

PMID:
10954060
14.

Sertindole : a review of its use in schizophrenia.

Murdoch D, Keating GM.

CNS Drugs. 2006;20(3):233-55. Review.

PMID:
16529528
15.

The effect of sertindole on QTD and TPTE.

Nielsen J, Andersen MP, Graff C, Kanters JK, Hardahl T, Dybbro J, Struijk JJ, Meyer JM, Toft E.

Acta Psychiatr Scand. 2010 May;121(5):385-8. doi: 10.1111/j.1600-0447.2009.01534.x.

PMID:
20085555
16.

A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia.

Azorin JM, Strub N, Loft H.

Int Clin Psychopharmacol. 2006 Jan;21(1):49-56.

PMID:
16317317
17.

Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.

Nielsen J, Emborg C, Gydesen S, Dybbro J, Aagaard J, Haderup K, Glyngdal P, Fabricius S, Thode D, Lublin H, Andersen T, Damkier P, Taylor D.

J Clin Psychopharmacol. 2012 Apr;32(2):173-8. doi: 10.1097/JCP.0b013e318248dfb8.

PMID:
22367659
18.

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB.

Am J Psychiatry. 1997 Jun;154(6):782-91.

PMID:
9167505
19.

Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.

[No authors listed]

Prescrire Int. 2007 Apr;16(88):59-62.

PMID:
17458045
20.

Do we need another atypical antipsychotic?

Kasper S.

Eur Neuropsychopharmacol. 2008 Aug;18 Suppl 3:S146-52. doi: 10.1016/j.euroneuro.2008.04.006. Review.

PMID:
18511242

Supplemental Content

Support Center